(Q34768847)

4 August 2017

1 reference

title

Antiepileptic drugs in psychiatry-focus on randomized controlled trial (English)

1 reference

4 August 2017

0 references

David J Muzina

1

1 reference

PubMed ID

12151129

4 August 2017

Samar El-Sayegh

series ordinal

2

1 reference

PubMed ID

12151129

4 August 2017

Joseph R Calabrese

series ordinal

3

1 reference

4 August 2017

1 June 2002

1 reference

4 August 2017

1 reference

4 August 2017

50

1 reference

4 August 2017

1-2

1 reference

4 August 2017

195-202

1 reference

Antiepileptic drugs in the 21st century.

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

Mood stabilizer combinations: a review of safety and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

Hematological effects of carbamazepine in patients with affective illness

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

Update on the mechanism of action of antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

Effects of carbamazepine and lithium on affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

Treatment of social phobia with gabapentin: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

Placebo-controlled study of gabapentin treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

Correlates of antimanic response to carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

Seizure severity and the quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900080-3

7 January 2021

10.1016/S0920-1211(02)00080-3

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12151129